

Publication Instructions:
BMT CTN Protocol 0501
- Primary and Ancillary Studies –

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 0501 and 0501 ancillary study: TREC Analysis For de novo T Cell Generation, T Cell Response Assays to HSV, CMV, VZV, Tetanus and PRP Antigens and Measurement of PRP and Tetanus Antibody Titers. Please contact the email below for other ancillary studies.

Acknowledgment Requirements:

For all Publications, Reports, Publications, Symposiums, etc.

“Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute, along with funding by the Children’s Oncology Group. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties.”

The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:

The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHS234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

Review Requirements:

For all Publications, Reports, Publications, Symposiums, etc.

BMT CTN: Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

The Children’s Oncology Group needs to review publications prior to release.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at NMDP_BMTCTN_Pub@nmdp.org.